1. AF1q is a universal marker of neuroblastoma that sustains N-Myc expression and drives tumorigenesis.
- Author
-
Lee, Joanna, Asgharzadeh, Shahab, Khan, Ranjha, Zhang, Meng, Weisbrod, Julia, Choi, Youn-Jeong, Puri, Latika, Aguilar, Ana, Zhao, Piming, Saba, Julie, and Oskouian, Babak
- Subjects
Child ,Humans ,N-Myc Proto-Oncogene Protein ,Neuroblastoma ,Oncogene Proteins ,Cell Transformation ,Neoplastic ,Transcription Factors ,Carcinogenesis ,Cell Line ,Tumor ,Gene Expression Regulation ,Neoplastic - Abstract
Neuroblastoma is the most common extracranial malignant tumor of childhood, accounting for 15% of all pediatric cancer deaths. Despite significant advances in our understanding of neuroblastoma biology, five-year survival rates for high-risk disease remain less than 50%, highlighting the importance of identifying novel therapeutic targets to combat the disease. MYCN amplification is the most frequent and predictive molecular aberration correlating with poor outcome in neuroblastoma. N-Myc is a short-lived protein primarily due to its rapid proteasomal degradation, a potentially exploitable vulnerability in neuroblastoma. AF1q is an oncoprotein with established roles in leukemia and solid tumor progression. It is normally expressed in brain and sympathetic neurons and has been postulated to play a part in neural differentiation. However, no role for AF1q in tumors of neural origin has been reported. In this study, we found AF1q to be a universal marker of neuroblastoma tumors. Silencing AF1q in neuroblastoma cells caused proteasomal degradation of N-Myc through Ras/ERK and AKT/GSK3β pathways, activated p53 and blocked cell cycle progression, culminating in cell death via the intrinsic apoptotic pathway. Moreover, silencing AF1q attenuated neuroblastoma tumorigenicity in vivo signifying AF1qs importance in neuroblastoma oncogenesis. Our findings reveal AF1q to be a novel regulator of N-Myc and potential therapeutic target in neuroblastoma.
- Published
- 2024